Modality
Gene Editing
MOA
BCL-2i
Target
IL-17A
Pathway
Ferroptosis
MyelofibrosisSchizophreniaT2D
Development Pipeline
Preclinical
~Sep 2022
→ ~Dec 2023
Phase 1
Mar 2024
→ Apr 2028
Phase 1Current
NCT03228205
214 pts·Myelofibrosis
2024-03→2028-04·Recruiting
214 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-04-032.0y awayPh2 Data· Myelofibrosis
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P1/2
Recruit…
Catalysts
Ph2 Data
2028-04-03 · 2.0y away
Myelofibrosis
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03228205 | Phase 1/2 | Myelofibrosis | Recruiting | 214 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D | |
| HAL-996 | Halozyme | Phase 1/2 | BCL-2 |